• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钾离子竞争性酸阻滞剂抵抗性非糜烂性反流病的发病机制。

Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.

出版信息

Digestion. 2018;98(3):194-200. doi: 10.1159/000488530. Epub 2018 Jun 5.

DOI:10.1159/000488530
PMID:29870976
Abstract

BACKGROUND

The present study examined the pathogenesis of potassium-competitive acid blocker (P-CAB)-resistant non-erosive reflux disease (NERD).

METHODS

Forty-three patients with NERD, who had persistent reflux symptoms despite the administration of P-CAB, were included in this study. After excluding eosinophilic esophagitis and primary esophageal motility disorders, esophageal impedance-pH monitoring was performed. In symptom index (SI)-positive patients, the mechanism of SI-positivity and percent time with intragastric pH > 4 and with esophageal pH < 4 were investigated according to the presence or absence of Helicobacter pylori infection.

RESULTS

One (2.3%) of 43 patients had a primary esophageal motility disorder (Jackhammer esophagus). Eighteen (41.9%) and 3 (7%) patients were SI-positive for liquid and gas-only reflux, respectively, and the remaining 21 patients who were SI-negative (48.8%) had functional heartburn. All patients SI-positive for liquid reflux were SI-positive for weakly acidic reflux. Gastric acid was sufficiently suppressed by P-CAB, regardless of the presence or absence of H. pylori infection.

CONCLUSIONS

The pathogenesis of -P-CAB-resistant NERD was elucidated in 51% of patients. Symptoms in all patients SI-positive for liquid reflux were related to weakly acidic reflux, and symptoms related to acid reflux may be ruled out by the administration of P-CAB.

摘要

背景

本研究旨在探讨钾竞争性酸阻滞剂(P-CAB)抵抗型非糜烂性反流病(NERD)的发病机制。

方法

纳入 43 例 P-CAB 治疗后仍持续存在反流症状的 NERD 患者。排除嗜酸性粒细胞性食管炎和原发性食管动力障碍后,进行食管阻抗-pH 监测。在症状指数(SI)阳性患者中,根据是否存在幽门螺杆菌感染,研究 SI 阳性的机制以及胃内 pH 值>4 和食管 pH 值<4 的时间百分比。

结果

43 例患者中,1 例(2.3%)存在原发性食管动力障碍(痉挛性食管)。18 例(41.9%)和 3 例(7%)患者液体反流和仅气体反流的 SI 分别为阳性,其余 21 例 SI 阴性(48.8%)的患者为功能性烧心。所有液体反流 SI 阳性的患者均为弱酸性反流 SI 阳性。无论是否存在幽门螺杆菌感染,P-CAB 均能充分抑制胃酸。

结论

51%的 P-CAB 抵抗型 NERD 患者的发病机制得到阐明。所有液体反流 SI 阳性的患者的症状均与弱酸性反流有关,通过 P-CAB 的给药可排除与酸反流相关的症状。

相似文献

1
Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.钾离子竞争性酸阻滞剂抵抗性非糜烂性反流病的发病机制。
Digestion. 2018;98(3):194-200. doi: 10.1159/000488530. Epub 2018 Jun 5.
2
Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection.双倍剂量质子泵抑制剂抵抗性非糜烂性反流病的发病机制,以及在存在或不存在幽门螺杆菌感染情况下反流症状及胃酸分泌抑制作用的机制
Digestion. 2017;95(2):140-145. doi: 10.1159/000455834. Epub 2017 Feb 4.
3
Determinants of reflux perception in patients with non-erosive reflux disease who have reflux-related symptoms on potassium-competitive acid blocker therapy.在接受钾离子竞争性酸阻滞剂治疗的非糜烂性反流病患者中,反流相关症状患者的反流感知决定因素。
Esophagus. 2022 Apr;19(2):367-373. doi: 10.1007/s10388-021-00889-z. Epub 2021 Oct 15.
4
Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.质子泵抑制剂难治性非糜烂性反流病的发病机制:多通道腔内阻抗-pH 监测研究。
J Gastroenterol Hepatol. 2012 Apr;27 Suppl 3:58-62. doi: 10.1111/j.1440-1746.2012.07074.x.
5
Evaluation of proton pump inhibitor-resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring.通过食管测压及24小时食管阻抗和pH监测评估质子泵抑制剂抵抗性非糜烂性反流病
Digestion. 2015;91(1):19-25. doi: 10.1159/000368766. Epub 2015 Jan 20.
6
Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.胃食管反流病症状患者经经验性质子泵抑制剂治疗失败后的多模态评估。
Dis Esophagus. 2013 Jul;26(5):443-50. doi: 10.1111/j.1442-2050.2012.01381.x. Epub 2012 Aug 2.
7
The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.换用新型钾离子竞争性酸阻滞剂沃克瑞对质子泵抑制剂难治性糜烂性食管炎患者胃酸分泌及反流模式的影响
Digestion. 2017;96(1):52-59. doi: 10.1159/000478255. Epub 2017 Jun 30.
8
Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure.弱酸性反流的较低pH值作为食管酸暴露正常的胃食管反流病患者烧心感知的决定因素。
Dis Esophagus. 2016 Jan;29(1):3-9. doi: 10.1111/dote.12284. Epub 2014 Sep 12.
9
[Non-erosive gastroesophageal reflux disease. Incidence of clinical forms, characteristics of esophageal exposure to acid and symptomatic correlations].[非糜烂性胃食管反流病。临床类型的发生率、食管酸暴露特征及症状相关性]
Rev Gastroenterol Mex. 2003 Apr-Jun;68(2):113-9.
10
Usefulness of baseline impedance in patients with proton pump inhibitor-refractory nonerosive reflux disease.基线阻抗在质子泵抑制剂难治性非糜烂性反流病患者中的应用价值
J Gastroenterol Hepatol. 2015 Mar;30 Suppl 1:36-40. doi: 10.1111/jgh.12743.

引用本文的文献

1
Current research status and trends of potassium-competitive acid blockers in the treatment of acid-related diseases: a bibliometric analysis.钾离子竞争性酸阻滞剂治疗酸相关性疾病的研究现状与趋势:一项文献计量学分析
Front Pharmacol. 2025 Jan 7;15:1477633. doi: 10.3389/fphar.2024.1477633. eCollection 2024.
2
Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments.钾离子竞争型酸阻断剂:当前临床应用与未来发展。
Curr Gastroenterol Rep. 2024 Nov;26(11):273-293. doi: 10.1007/s11894-024-00939-3. Epub 2024 Aug 15.
3
A scientometrics analysis and visualization of refractory gastroesophageal reflux disease.
难治性胃食管反流病的科学计量学分析与可视化
Front Pharmacol. 2024 Jul 30;15:1393526. doi: 10.3389/fphar.2024.1393526. eCollection 2024.
4
Trends in gastroesophageal reflux disease research: A bibliometric and visualized study.胃食管反流病研究趋势:一项文献计量学与可视化研究
Front Med (Lausanne). 2022 Sep 29;9:994534. doi: 10.3389/fmed.2022.994534. eCollection 2022.
5
Potent Acid Suppression with PPIs and P-CABs: What's New?质子泵抑制剂和钾离子竞争性酸阻滞剂的强效抑酸作用:有哪些新进展?
Curr Treat Options Gastroenterol. 2018 Dec;16(4):570-590. doi: 10.1007/s11938-018-0206-y.